Ken Griffin Passage Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.64 - $1.0 $384 - $600	-600 Reduced 7.23%	7,700 $5,000
Q2 2024 Aug 14, 2024	SELL	$0.79 - $1.58 $9,480 - $18,960	-12,000 Reduced 59.11%	8,300 $6,000
Q1 2024 May 15, 2024	BUY	$0.86 - $1.73 $16,082 - $32,351	18,700 Added 1168.75%	20,300 $27,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.01 $3,000 - $5,050	-5,000 Reduced 75.76%	1,600 $1,000
Q3 2023 Nov 14, 2023	BUY	$0.66 - $1.01 $3,234 - $4,949	4,900 Added 288.24%	6,600 $4,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.19 $245 - $357	-300 Reduced 15.0%	1,700 $1,000
Q1 2023 May 15, 2023	SELL	$0.96 - $1.88 $15,840 - $31,020	-16,500 Reduced 89.19%	2,000 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.06 - $1.48 $31,694 - $44,252	-29,900 Reduced 61.78%	18,500 $25,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $2.48 $59,048 - $120,032	48,400 New	48,400 $61,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $40.8M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.